- Home
- MTEK vs APLM Comparison
MTEK vs APLM Comparison
Compare MTEK & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- APLM
- Stock Information
- Founded
- MTEK 2008
- APLM 2016
- Country
- MTEK Israel
- APLM United States
- Employees
- MTEK N/A
- APLM N/A
- Industry
- MTEK
- APLM Blank Checks
- Sector
- MTEK
- APLM Finance
- Exchange
- MTEK Nasdaq
- APLM Nasdaq
- Market Cap
- MTEK N/A
- APLM 6.9M
- IPO Year
- MTEK 2022
- APLM N/A
- Fundamental
- Price
- MTEK $3.26
- APLM $5.33
- Analyst Decision
- MTEK
- APLM
- Analyst Count
- MTEK 0
- APLM 0
- Target Price
- MTEK N/A
- APLM N/A
- AVG Volume (30 Days)
- MTEK 167.6K
- APLM 27.3K
- Earning Date
- MTEK 08-27-2025
- APLM 08-13-2025
- Dividend Yield
- MTEK N/A
- APLM N/A
- EPS Growth
- MTEK N/A
- APLM N/A
- EPS
- MTEK N/A
- APLM N/A
- Revenue
- MTEK $6,078,953.00
- APLM $198,000.00
- Revenue This Year
- MTEK N/A
- APLM $415.15
- Revenue Next Year
- MTEK N/A
- APLM N/A
- P/E Ratio
- MTEK N/A
- APLM N/A
- Revenue Growth
- MTEK 50.80
- APLM N/A
- 52 Week Low
- MTEK $1.48
- APLM $4.47
- 52 Week High
- MTEK $6.47
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- MTEK 60.44
- APLM 44.49
- Support Level
- MTEK $3.00
- APLM $5.33
- Resistance Level
- MTEK $3.42
- APLM $6.56
- Average True Range (ATR)
- MTEK 0.27
- APLM 0.54
- MACD
- MTEK 0.00
- APLM -0.05
- Stochastic Oscillator
- MTEK 67.03
- APLM 33.11
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.